Cargando…

Prospective Studies on the Risk of Rheumatoid Arthritis: The European Risk RA Registry

BACKGROUND: The accumulation of risk for the development of rheumatoid arthritis (RA) is regarded as a continuum that may start with interacting environmental and genetic factors, proceed with the initiation of autoimmunity, and result in the formation of autoantibodies such as anti-citrullinated pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Studenic, Paul, Hensvold, Aase, Kleyer, Arnd, van der Helm-van Mil, Annette, Pratt, Arthur G., Sieghart, Daniela, Krönke, Gerhard, Williams, Ruth, de Souza, Savia, Karlfeldt, Susanne, Johannesson, Martina, Krogh, Niels Steen, Klareskog, Lars, Catrina, Anca I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901993/
https://www.ncbi.nlm.nih.gov/pubmed/35273981
http://dx.doi.org/10.3389/fmed.2022.824501
Descripción
Sumario:BACKGROUND: The accumulation of risk for the development of rheumatoid arthritis (RA) is regarded as a continuum that may start with interacting environmental and genetic factors, proceed with the initiation of autoimmunity, and result in the formation of autoantibodies such as anti-citrullinated peptide antibodies (ACPA). In parallel, at-risk individuals may be asymptomatic or experience joint pain (arthralgia) that is itself non-specific or clinically suspicious for evolving RA, even in the absence of overt arthritis. Optimal strategies for the management of people at-risk of RA, both for symptom control and to delay or prevent progression to classifiable disease, remain poorly understood. METHODS: To help address this, groups of stakeholders from academia, clinical rheumatology, industry and patient research partners have collaborated to advance understanding, define and study different phases of the at-risk state. In this current report we describe different European initiatives in the field and the successful effort to build a European Registry of at-risk people to facilitate observational and interventional research. RESULTS: We outline similarities and differences between cohorts of at-risk individuals at institutions spanning several countries, and how to best combine them within the new database. Over the past 2 years, besides building the technical infrastructure, we have agreed on a core set of variables that all partners should strive to collect for harmonization purposes. CONCLUSION: We emphasize to address this process from different angles and touch on the biologic, epidemiologic, analytic, and regulatory aspects of collaborative studies within a meta-database of people at-risk of RA.